Physician profile
Tania Arreguin
NPI 1497389415
$933.61
in general payments reported to CMS, 2019-2025
16 companies · $934 in 2025
The $934 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $934.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $934.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $933.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $300.29 | 2025 | |
| Ani Pharmaceuticals, INC. | $145.36 | 2025 | Purified Cortrophin Gel |
| Penumbra, INC. | $102.35 | 2025 | Indigo System |
| Janssen Biotech, INC. | $73.08 | 2025 | Tremfya |
| Amgen INC. | $45.40 | 2025 | Tavneos, Otezla |
| Lilly USA, LLC | $45.28 | 2025 | Ebglyss, Taltz |
| Tonix Medicines, INC. | $32.50 | 2025 | Tonmya |
| Radius Health, INC. | $30.28 | 2025 | Tymlos |
| Leo Pharma INC. | $26.27 | 2025 | Anzupgo |
| Vanda Pharmaceuticals INC. | $24.70 | 2025 | Hetlioz, Fanapt |
| Alexion Pharmaceuticals, INC. | $22.37 | 2025 | Strensiq |
| Ucb, INC. | $20.01 | 2025 | Bimzelx |
| Astrazeneca Pharmaceuticals LP | $19.97 | 2025 | |
| Glaxosmithkline, LLC. | $16.42 | 2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $15.84 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $13.49 | 2025 | Lupkynis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tania Arreguin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.